Peripheral Blood-Derived CircVPS35L as a Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer
Oncology · 2023
DOI: 10.1159/000531357 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, 2023. Verfasst von Nan Liang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology and Zhejiang Key Laboratory of Pathophysiology, School of Basic Medical Sciences, Health Science Cen…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Lung Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Introduction
Circular RNAs (circRNAs) are dysregulated in cancers and are stably expressed in body fluids such as blood. We therefore identified and evaluated the clinical value of a newly found circRNA VPS35L (circVPS35L) as a biomarker for the diagnosis of non-small cell lung cancer (NSCLC).
Methods
Reverse-transcription quantitative PCR (RT-qPCR) was used to determine the expression levels of circVPS35L in tissues, whole blood, and cell lines. The actinomycin D assay and RNase R treatment were utilized to determine the stability of circVPS35L. Receiver operating characteristic (ROC) curve analysis was conducted to predict the diagnostic value of blood-derived circVPS35L in NSCLC.
Results
CircVPS35L was found to be downregulated in NSCLC tissues and cell lines. Interestingly, circVPS35L expression was significantly correlated with tumor size (p = 0.0269), histology type (p < 0.0001), and TNM stage (p = 0.0437). Importantly, circVPS35L was poorly expressed in peripheral blood of NSCLC patients when compared with healthy controls and patients with benign lung disease. ROC analysis revealed a higher diagnostic value of circVPS35L than the three conventional tumor markers (CYFR21-1, NSE, and CEA) in patients with NSCLC. Moreover, circVPS35L was highly stable in peripheral blood when exposed to undesirable conditions.
Conclusion
These findings demonstrate that circVPS35L has great potential as a novel biomarker for the diagnosis of NSCLC and can be used to distinguish NSCLC from benign lung disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology and Zhejiang Key Laboratory of Pathophysiology, School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
- Department of Thoracic Surgery, The Affiliated First Hospital of Ningbo University, Ningbo, China.
- Department of Chemoradiotherapy, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
Zitieren
APA
Liang, N., Zhang, X., Zhang, L., Jiang, M., Bai, H., Ding, C., Cai, Y., Zhou, C., Han, Y., & Gong, Z. (2023). Peripheral Blood-Derived CircVPS35L as a Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer. Oncology. https://doi.org/10.1159/000531357
Vancouver
Liang N, Zhang X, Zhang L, Jiang M, Bai H, Ding C, et al. Peripheral Blood-Derived CircVPS35L as a Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer. Oncology. 2023. doi:10.1159/000531357
BibTeX
@article{Liang2023,
author = {Liang, Nan and Zhang, Xun and Zhang, Luyi and Jiang, Meina and Bai, Huihui and Ding, Chenhang and Cai, Yuanting and Zhou, Chengwei and Han, Ying and Gong, Zhaohui},
title = {Peripheral Blood-Derived CircVPS35L as a Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer},
journal = {Oncology},
year = {2023},
doi = {10.1159/000531357}
}
EUVIMED